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Abstract 
In this study, the plant based biopolymeric fraction RLJ-NE-205 isolated from Picrorhiza kurroa were 
evaluated for its potential ability as an adjuvant effect on the immune responses to Ovalbumin (specific 
antigen) in mice. Immunization in Balb/C mice with variable doses of RLJ-NE-205 (10 – 80 g) with optimized 
dose of Ovalbumin (100 g) dissolved in phosphate buffered saline or containing alum (200 g) on Days 1 
and 15. After two weeks of the challenging dose, OVA specific antibodies in serum, spleen cell proliferation 
assay, estimation of Th1 (IL-2/IFN-gamma) and Th2 (IL-4) cytokines in serum, CD3/CD4/CD8/CD19 surface 
markers of T and B cell, costimulatory molecules (CD80/CD86) in spleen cells and safety studies were 
observed. The results suggest that OVA mediated specific antibody levels (IgG, IgG1 and IgG2a) in serum 
were significantly enhanced by RLJ-NE-205 (20 g) containing 100 g OVA compared with OVA control 
group. Moreover, RLJ-NE-205 (20 g) containing 100 g OVA on IgG, IgG1, and IgG2a antibody responses 
to OVA in mice were more significant than those of alum. RLJ-NE-205 (20 g) significantly enhanced the OVA 
induced spleen cell proliferation and estimation of Th1 and Th2 cytokines in the OVA immunized mice. 
However, no significant differences were observed among the OVA group and OVA/alum group. At the dose 
of 100 g OVA containing 20 g RLJ-NE-205, there was a significant increase in the Th1 and Th2 cytokines in 
serum and CD3/CD4/CD8/CD19 surface markers and costimulatory molecules (CD80/CD86) in the spleen 
cell by flow cytometry were observed.  
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Introduction 
A body of evidence showed that numerous bioactive polysaccharides isolated from herbal plants have 
immunomodulation and anti-cancer effects. Previous studies have shown that polysaccharides evoke stronger immune 
responses than alum or others [1, 2, 3, 4, 5]. Thus, the polysaccharides from medicinal herbs are becoming an attractive 
material as pharmaceutical products and may provide an opportunity to develop a new adjuvant for vaccine antigen. 
Indeed, a wide range of bioactive polysaccharides have been isolated from various medicinal plants and these 
polysaccharides have been shown to possess immunomodulatory activity through their ability to modulate macrophage 
function [3, 4]. Appropriate enhancement of innate immune functions by bioactive compounds can then augment host 
defense responsiveness because of their minute toxicity and high potency of these molecules, plant polysaccharides 
represent one of the ideal or best candidates for therapeutics with immunomodulatory action. 
Picrorhiza kurroa is a well known herb in the Ayurvedic system of medicine (belongs to the family Scrophulariaceae) 
and has traditionally been used to treat disorders i.e. liver, upper respiratory tract, scorpion sting etc [6, 7]. The leaves of 
the Picrorhiza kurroa are flat, oval and sharply serrated and  flowers generally appeared from June to August and the 
manual harvesting of the plant from October to December. Most of the active constituents are generally obtained from 
the root and rhizomes. In our previous paper, we isolated active polysaccharide fraction (RLJ-NE-205) from Picrorhiza 
Kurroa that induce both humoral and cellular arms of the immune system in Balb/C mice [8]. Similarly, a number of 
polysaccharides that provoke immune responses and anti-tumor activities via macrophage activation have been purified 
from higher plants and mushrooms [9], [10], [11] and [12]. A better understanding of the biology of T cell 
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subpopulations viz. CD4/CD8, T and B cell memory, regulatory T cells and mucosal immunity has profound 
implications for a modern approach to adjuvant screening and development. The present study was undertaken to validate 
the immunoadjuvant effects of RLJ-NE-205 against weak antigen ovalbumin. 
Materials and Methods 
Preparation of Biopolymeric fraction RLJ-NE-205 from Picrorhiza kurroa  
The organic solvent exhausted material (0.5 kg) of the plant Picrorhiza kurroa was soaked in 2 M aqueous sodium 
hydroxide and kept at 4 °C overnight. The extract was filtered and the alkaline solution centrifuged at 6000 – 7000 r. 
p.m. at 4 °C. The above process was repeated and the aqueous alkaline solution was pooled with the first extract. The 
combined extracts were diluted with alcohol (1: 6) and kept overnight (4 °C). The precipitate was collected through 
centrifugation at 6000 – 7000 r. p.m. and dissolved in distilled water (400 ml), acidified with equal volume of 15 % aq. 
TCA and kept overnight at 4 °C. The precipitated biopolymeric fraction coded as RLJ-NE-205 (3.5 g) obtained by 
centrifugation was suspended in warm distilled water (500 ml) and centrifuged. The aqueous solution was lyophilized 
and fraction RLJ-NE-205 (3.0 g) was obtained as an amorphous solid. From HPLC of the hydrolysed (2N - TFA) 
biopolymeric fraction RLJ-NE-205 in comparison to authentic monosaccharides it was observed that biopolymeric 
fraction is composed of glucose, xylose, galactose and arabinose in the molar ratio of 3.0, 1.0, 1.8 and 4.1. A flow sheet 
is represented as shown in Fig.1.  
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Animals 
Male adult Balb/C mice 10 – 12 weeks old and weighing 20 – 22 g obtained from the animal house of the Indian 
Institute of Integrative Medicine (IIIM), Jammu in groups of 5 - 10 were employed for the study and kept in plastic 
cages. These were maintained at a room temperature of 22 ± 2 °C with 12 h light/dark cycle and free access to pellet 
food (Lipton India limited) and water. The ethical committee of the Indian Institute of Integrative Medicine (IIIM) 
instituted for animal handling approved all protocols. 
Immunization 
In order to find out the adjuvant activity of biopolymeric fraction RLJ-NE-205 with ovalbumin antigen. Animals were 
immunized s.c. with 100 μg OVA formulated with one of the following delivery vehicles: Phosphate buffered saline and 
RLJ-NE-205 (10, 20, 40 and 80 μg) on Day 1. Saline-treated animals were included as controls. A challenging injection 
was given two weeks later. Control adjuvant (standard) was alum (200 μg). Alum was formulated with OVA at a ratio of 
two parts adjuvant to one part antigen immediately prior to administration. The resultant formulation was thoroughly 
vortexed before use. In every experiment, one group was kept as control, whilst another group received standard drug for 
comparison of the study and authenticity of the experiment. 
Assay of IgG (anti-OVA) titre in the sera of mice by Elisa 
OVA specific IgG antibodies in serum were detected by an indirect ELISA [13]. In brief, microtiter plate wells were 
coated with 100 μl OVA solution (50 μg/ml) for IgG antibodies in 50 mM carbonate-bicarbonate buffer, pH 9.6) for 24 h 
at 4 °C. The wells were washed three times with PBS containing 0.05 % (v/v) Tween 20 (PBS/Tween) and then blocked 
with 5 % FCS/PBS at 37 °C for 1 h. After three washings, 100 μl of diluted serum sample (IgG, 1: 400) or 0.5 % 
FCS/PBS as control was added to duplicate/triplicate wells. The flat bottom 96 well Elisa plates were then again 
incubated for additional 1 h at 37 °C, followed by three times of washing. Add rabbit anti-mouse IgG horse radish 
peroxidase conjugate (100 μl) diluted 1 : 1000 with 0.5 % FCS/PBS were added. Elisa plates were further incubated for 
1 h at 37 °C. After washing, the peroxidase activity was assayed as following: 100 μl of substrate solution (10 mg of o-
phenylenediamine and 37.5 μl of 30 % H2O2 in 25 ml of 0.1 M citrate-phosphate buffer, pH 5.0) was added. The flat 
bottom Elisa plate plate was again incubated for additional 10 min at 37 °C and then suddenly stop solution was added. 
The optical density (OD) was measured in an ELISA reader at 450 nm. 
Assay of IgG1 and IgG2a (anti-OVA) titre in the sera of mice by Elisa  
OVA specific IgG1 and IgG2a antibodies in serum were detected by an indirect ELISA [13]. In brief, microtiter plate 
wells were coated with 100 μl OVA solution (25 and 50 μg/ml) for IgG1 and IgG2a antibodies, respectively, in 50 mM 
carbonate-bicarbonate buffer, pH 9.6) for 24 h at 4 °C. The wells were washed three times with PBS containing 0.05 % 
(v/v) Tween 20 (PBS/Tween), and then blocked with 5 % FCS/PBS at 37 °C for 1 h. After three washings, 100 μl of 
diluted serum sample (IgG1, 1:100; IgG2a, 1:200) or 0.5 % FCS/PBS as control was added to duplicate/triplicate wells. 
The flat bottom 96 well Elisa plates were then again incubated for 1 h at 37 °C, followed by three times of washing. 
Aliquots of 100 μl of goat anti-mouse IgG1 peroxidase conjugate 1: 500 or IgG2a peroxidase conjugate 1: 100 with 0.5 
% FCS/PBS were added. The flat bottom 96 well Elisa plates were further incubated for 1 h at 37 °C. After washing, the 
peroxidase activity was assayed as following: 100 μl of substrate solution was added to each well. The plate was 
incubated for 10 min at 37 °C, and enzyme reaction was terminated by adding 50 μl/well of 2 N H2SO4. The OD was 
measured in an ELISA reader at 450 nm. 
Splenocyte proliferation assay (ex vivo) 
Mice were sacrificed by carbon dioxide anesthesia. The spleens were excised aseptically and lymphocytes isolated. 
Briefly, single cell suspensions were prepared by teasing the tissue between two glass slides and cells were centrifuged at 
1800 rpm for 10 min at 4 °C. Erythrocytes present were lysed with red cell lysis buffer for 5 min. Lymphocytes obtained 
were then washed thrice with PBS. Count the number of cells using haemocytometer and determined by trypan blue dye 
exclusion technique. Cell viability exceeded 95 % [14].  
To evaluate the effect of biopolymeric fraction RLJ-NE-205 on the proliferation of splenic lymphocytes [8], spleen cell 
suspension (2 × 10
6
 cell/ml) was pipetted into 96 well plates (200 μl/well) in the presence of OVA (5 µg/ml) cultured at 
37 °C for 48 h, the plates were centrifuged at 1800 rpm, 5 min and the supernatant was collected for the estimation of 
cytokines in cell culture supernatant and add fresh 100 µl fresh complete media in 96 well plate and again incubate for 
24 h and then add 20 μl of MTT solution (5 mg/ml) were added to each well and incubated for 4 h. The plates were 
centrifuged (1400 × g, 5 min) and the untransformed MTT was removed carefully by pipetting. Add 100 μl of a DMSO 
was added and the absorbance was evaluated in an ELISA reader at 570 nm after 15 min. 
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Estimation of Th1 and Th2 cytokines in serum 
Cytokine concentrations in the serum were determined by ELISA kits that were specific against murine cytokines. Levels 
of Th1 (IFN-γ, IL-2) and Th2 (IL-4) cytokines were measured using ELISA (Quantikine, ELISA kits). Assays were 
performed according to the manufacturer's instructions [15, 16].  
Lymphocyte immunophenotyping (CD3/CD4/CD8/CD19) and costimulatory molecules estimation in 
spleen 
The percentages of T lymphocyte subsets in the spleen were measured using flow cytometric analysis [8]. Spleen single 
cell suspensions were dually labeled with FITC-conjugated and PE- conjugated antibodies.  
The spleen (1/3 of the organ) was placed in PBS buffer (without Mg
2+
 and Ca
2+
) stored on ice prior to preparation of 
single cell suspensions. Splenic erythrocytes (RBC’s) were lysed with FACS lysing solution/red blood cell lysing 
buffer/ACK lysis buffer. Cell suspensions were refrigerated at 4C pending staining with antibodies. For each sample, 2 
x 10
6
 cells were stained with conjugated anti-CD80 (B7-1), anti-CD3 & CD4 FITC and anti-CD86 (B7-2), anti-CD8a & 
CD19 PE antibodies. After staining with flow cytometric antibodies, cells were washed two to three times with wash 
buffer and finally resuspended in PBS for flow cytometric analysis. The forward and side scatter gating applied for data 
acquisition of cell surface markers on 10,000 events and fraction of cell populations representing different phenotypes 
analyzed using cell quest software (FACS calibur, Becton Dickinson). 
Safety studies 
Safety of the active adjuvant candidate with OVA was proven by injecting it intraperitoneally into mice. Balb/c mice 
were divided into groups of 10 animals each and were inoculated with variable doses of RLJ-NE-205 and OVA, which 
had been resuspended in PBS. Control mice, received PBS. After injection, mice were observed daily for a period of 8 
weeks. Deviations from their normal behavior or reactions at the injection site were recorded. The weight of the mice was 
taken on days 0, 24, 28 and 60 post-injection. 
Statistical analysis 
Data were expressed as mean ± S.E. and statistical analysis was carried out using one-way ANOVA (Bonferroni 
correction multiple comparison test). 
Results 
Effect of biopolymeric fraction RLJ-NE-205 on humoral response against OVA-specific antibody viz. 
IgG, IgG1 and IgG2a titre 
OVA specific IgG, IgG1 and IgG2a antibody levels in the sera were measured two weeks after the last immunization, 
there is a significant enhancement in total serum IgG, IgG1 and IgG2a levels were observed (Fig.2) in the group of 
biopolymeric fraction  RLJ-NE-205. The impact of RLJ-NE-205 on the production of IgG isotype viz. IgG1 and IgG2a 
was monitored in sera of the animals. OVA immunized animals given different doses of RLJ-NE-205 showed dose 
dependent increase in the secretion of IgG, IgG1 and IgG2a, with maximum response at 20 g on day 15th and 28th and 
there was significantly higher when compared to the value of OVA group. There were significant differences among the 
total serum IgG2a levels in mice immunized with RLJ-NE-205. Alum (200 g) the standard adjuvant taken for 
comparison and authentication of the experimentation, increased IgG and IgG1 titre but poorly elicited IgG2a titre when 
compared to the value of OVA control group. Thus, findings indicate that biopolymeric fraction RLJ-NE-205 could 
significantly enhance serum antibody viz. IgG, IgG1 and IgG2a production as compared with alum. 
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Fig.2. Effect of biopolymeric fraction RLJ-NE-205 on OVA specific IgG, IgG1 and IgG2a antibody titre  
Groups of ten male Balb/c mice were immunized s.c. with OVA 100 μg alone or with OVA 100 μg dissolved in saline 
containing alum (200 μg) or RLJ-NE-205  (10, 20, 40 and 80 μg) on Days 0 and 15. Sera were collected two weeks after 
the last immunization. OVA-specific IgG, IgG1 and IgG2a antibodies in the sera were measured by an indirect ELISA 
method as described in materials and methods. The values are presented as mean ± S.E. and significant differences with 
control were designated as *P < 0.05, **P < 0.01, ***P < 0.001.  
Effect of biopolymeric fraction RLJ-NE-205 on cell mediated immune response against splenocyte 
proliferation assay (ex vivo)  
The effect of biopolymeric fraction RLJ-NE-205 on OVA stimulated splenocyte proliferation in mice immunized with 
OVA is shown in (Fig. 3). The results showed that biopolymeric fraction RLJ-NE-205 significantly enhanced the cell 
mediated immune response when compared to the OVA control group. RLJ-NE-205 at 20 µg significantly enhanced 
proliferative response to OVA was observed when compared to the control group. Alum (200 µg) the standard adjuvant 
used in this test model, enhanced proliferative response to OVA when compared to the control animals. The results 
indicated that biopolymeric fraction RLJ-NE-205 significantly enhanced the splenocyte proliferation assay as compared 
with alum. 
 
 
Fig.3. Effect of biopolymeric fraction RLJ-NE-205 on OVA stimulated splenocyte proliferation assay 
(ex vivo) 
 Splenocytes were prepared two weeks after the last immunization and cultured with OVA (5 g/ml) for 72 h. Splenocyte 
proliferation was measured by the MTT method as described in the materials and methods. Values are presented as 
mean ± S.E. and significant differences with control were designated as *P < 0.05, **P < 0.01, ***P < 0.001 when 
compared to the value of control. 
Effect of biopolymeric fraction RLJ-NE-205 on estimation of Th1 (IL-2/IFN-) and Th2 (IL-4) 
cytokines in serum 
The effect of biopolymeric fraction RLJ-NE-205 on Th1 (IL-2/IFN-) and Th2 (IL-4) cytokines in mice immunized 
with OVA is shown in (Fig. 4). The results showed that biopolymeric fraction RLJ-NE-205 significantly enhanced the 
Th1 (IL-2/IFN-) and Th2 (IL-4) cytokines when compared to the OVA control group. However, production of IL-2, 
IL-4 and IFN- γ level in serum was numerically higher in the mice immunized with 20 g RLJ-NE-205 than those of 
the mice immunized with OVA control group. However, no significant differences were observed between the OVA 
control group and OVA/alum. Alum (200 µg) the standard adjuvant, increased Th2 (IL-4) but inhibited the cytokine 
(IL-2 and IFN-γ) level in serum. The results indicated that biopolymeric fraction RLJ-NE-205 increased the cytokine 
(IL-2 and IFN-γ) and Th2 (IL-4) level in serum as compared with alum and control group.  
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Fig.4. Effect of biopolymeric fraction RLJ-NE-205 on Th1 and Th2 cytokine profile in serum 
Groups of ten male Balb/c mice were immunized s.c. with OVA 100 μg alone or with OVA 100 μg dissolved in saline 
containing alum (200 μg) or RLJ-NE-205 (10, 20, 40 and 80 μg) on Days 0 and 15. Sera were collected two weeks after 
the last immunization for the estimation of Th1 (IL-2 and IFN-gamma) and Th2 (IL-4) in serum. The results are 
presented as Mean ± S.E..  P values: *P < 0.05, **P < 0.01, ***P < 0.001 when compared to the value of control. 
Effect of biopolymeric fraction RLJ-NE-205 on lymphocyte immunophenotyping 
(CD3/CD4/CD8/CD19) and co-stimulatory molecules in spleen 
The effect of biopolymeric fraction RLJ-NE-205 on CD3
+ 
/CD4
+
/CD8
+
 T and CD19
+
 B cells in the spleen cells from the 
OVA immunized mice were shown in (Table 1). 
TABLE 1:- Effect of biopolymeric fraction RLJ-NE-205 on spleen T cell subtypes         (CD4 AND CD8) 
    S.NO. Treatment Doses 
(g) 
   Spleen T-cell subtypes (% Gated) 
CD4+CD8-           CD4-CD8+ 
1 Control - 14.2  1.7 9.6  1.3 
2 Alum 200 24.2  1.7** 10.3  0.7 
3 RLJ-NE-205 10 20.5  0.8 11.0  0.3 
4 RLJ-NE-205 20 28.6  0.9*** 15.7  1.0*** 
5 RLJ-NE-205 40 26.8  1.6** 13.1  0.78** 
6 RLJ-NE-205 80 19.2  1.3 10.6  1.1 
Flowcytometric analysis of T cell surface markers expression in splenocytes of RLJ-NE-205 treated mice. Cells were 
incubated with anti-mouse FITC-labeled CD4 and PE conjugated CD8 monoclonal antibodies. Data are Mean ± S.E. 
(n = 10). P values: *P < 0.05, **P < 0.01, ***P < 0.001 when compared to the value of control. 
 Although the proportions of CD3/CD4/CD8 T cell estimation in the spleen cells from the mice immunized with 20 µg 
RLJ-NE-205 and alum were higher than those from the OVA control group. CD3/CD19.  Similarly, the proportions of 
CD19 B cell estimation in the spleen cells from the mice immunized with 20 µg RLJ-NE-205 were higher than those 
from the OVA control group as shown in Fig. 5.  
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Fig.5. Effect of biopolymeric fraction RLJ-NE-205 on T (CD3) and B (CD19) cell surface markers on 
spleen cells by flow cytometry 
Flowcytometric analysis of T cell surface markers expression in splenocytes of RLJ-NE-205 treated mice. Cells were 
incubated with anti-mouse FITC-labeled CD3 and PE conjugated CD19 monoclonal antibodies 
In addition, Biopolymeric fraction RLJ-NE-205 significantly upregulated the costimulatory expression of both CD80 
and CD86 on splenic macrophages in a dose-dependent manner. Biopolymeric fraction RLJ-NE-205 at the dose of 20 
µg (optimum dose range) induced optimum enhancement of 2-fold in the number of cells expressing CD80/CD86 over 
the control animals (Fig.6) 
 
Fig.6. Effect of biopolymeric fraction RLJ-NE-205 on co-stimulatory molecules CD80 (B7-1) and CD86 
(B7-2) 
Flow cytometric analysis of the expression of co-stimulatory signal molecules in spleen-derived macrophages. Data 
represented by percent CD80/CD86 positive cell populations are mean ± S.E. (n=5); *P < 0.05, **P < 0.01, ***P < 0.001 
(control vs. RLJ-NE-205-treated groups; one-way ANOVA followed by Bonferroni multiple comparison test). 
Safety Studies 
No weight loss observed for mice when recorded on days 0, 15 and 28 post-injection. Mice were kept under observation 
for 28 days post-injection for any toxic manifestation and no visible symptoms or any other undesirable effects was 
observed after the treatment of biopolymeric fraction RLJ-NE-205. In our studies, 8 animals were taken up for safety 
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studies. These animals were kept in an isolator at a temperature of 25 

C. And the rectal temperature was measured twice 
daily.  Animal body weights were taken on 0, 7, 14 and 28
th
 day. Even though the fluctuation in body weights has been 
observed (data not shown), no significant fluctuation in body temperature was observed. 
Discussion 
Adjuvant research is a field that is advancing rapidly, reflecting high rate at which new adjuvants are being discovered. 
The requirement of a safe and effective adjuvant for current vaccines cannot be overstated. Newly developed vaccines 
are usually based on target antigen i.e specific and non-specific, they are usually weak immunogenic, costly/expensive 
and induce poor immunopharmacological responses. However, plant based adjuvants can override such immunological 
inadequancy and help in mounting protective humoral and cellular immune responses. There is a significant interest in 
developing vaccine adjuvant that combine the safety advantages of subunit or recombinant protein based vaccines with 
enhanced efficacy. However, many of them are not highly immunogenic whether administered parenterally or mucosally 
and approved adjuvants are ineffective in triggering immunity, thus identification of plant based adjuvant capable of 
facilitating antigen delivery to immune responsive cells and functioning as adjuvants. 
OVA is commonly used as a model for immunogen specific T and B cell mediated immune function. Biopolymeric 
fraction RLJ-NE-205 (20 μg) significantly enhanced OVA specific IgG and its isotypes IgG1 and IgG2a titres were 
observed in group of  immunized mice compared with OVA control and standard alum group. It is generally known that 
Con A stimulates T cell proliferation [17, 18]. When splenocytes separated from mice immunized with OVA were 
exposed to RLJ-NE-205, it is possible that lymphocytes recognize and receive second signals and test candidate viz. 
biopolymeric fraction RLJ-NE-205 could facilitate OVA specific lymphocytes to proliferate and differentiate into 
effector cells and memory cells [19].  
Cell mediated immunity, mediated by T lymphocytes, play an important role to combat intracellular infections. Among 
the T lymphocytes, helper T cells induce B lymphocytes to secrete antibodies and cytotoxic T lymphocytes help 
phagocytes to destroy infection induced by pathogen and to kill intracellular microbes. The capacity to elicit an effective 
T cell immunity can be shown by the stimulation of lymphocyte proliferation response and cytokine estimation. The 
results indicated that RLJ-NE-205 could significantly increase the activation potential of T (IgG2a) and B (IgG1) cells in 
OVA-immunized mice. RLJ-NE-205 also had a significant stimulatory effect on CD4+ and CD8+ T cells, thereby 
confirming its general effect on the cell-mediated immune response. Furthermore, co-stimulatory signals are the most 
important secondary signals playing an important role in the cell–cell cross-talk for the delivery of the required immune 
response. CD80 has been found to play key role in maintaining the state of immune response, where as another co-
stimulatory molecule i.e. CD86 plays a role in maintaining immune memory [20]. The expressions of CD80 and CD86 
on splenic macrophages of RLJ-NE-205-treated mice were found significantly enhanced supporting its potential of 
activating the antigen presenting cells through co-stimulatory signals that eventually help in the generation of effective 
immune response by secreting various signal molecules like cytokines and chemokines. 
Meanwhile, cytokine measurement also revealed that RLJNE-205 significantly promoted the production of the Th1 (IL-2 
and IFN-) and Th2 (IL-4) cytokines in OVA immunized mice. These results suggested that RLJ-NE-205, be able to 
simultaneously stimulate Th1 (IgG2a) and Th2 (IgG1) immune response. In our conditions, RLJ-NE-205 enhanced 
significantly a specific antibody and cellular response against OVA in mice. 
In conclusion, two important features of RLJ-NE-205 have been clearly shown: (1) RLJ-NE-205 is a strong Th1/Th2 
adjuvant for the OVA in the mice model and (2) the immunogenicity of the RLJ-NE-205-adjuvanted OVA is better than 
that of OVA adjuvanted with alum. The OVA-specific antibody immune response induced by RLJ-NE-205 was 
associated with higher antibody titers than that provided by the alum vaccine and moreover cell-mediated responses were 
elicited. Furthermore, RLJ-NE-205 also significantly enhanced the population of cell surface marker CD4/CD8 and co-
stimulatory molecules CD80/CD86. Thus, RLJ-NE-205 is a potent enhancer of antigen-specific humoral and cell-
mediated immune responses, thus showing promise as immune adjuvant for vaccines against intracellular infectious 
agents such as viruses, bacteria, protozoa and against cancer cells.  
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